Recent years have seen significant developments in the landscape of cell and gene therapies, with a notable increase in treatments available for rare and life-threatening diseases. These advancements come despite the generally high costs of research, development and manufacturing, compounded by the relative infancy of our understanding compared to other scientific domains.
Get data-driven insights on the current and future state of the cell and gene therapy landscape in Evaluate’s new report.
We investigate:
- Newly approved therapies and ongoing developments in the pipeline
- Focus areas: Indications receiving the most attention
- Competitive dynamics: Biotech vs. Big Pharma
- Current appetite for partnerships
- Future revenue drivers: Key therapies and disease areas
